Early Alzheimer’s patients continue to benefit from 4 yrs of LEQEMBI(R) (lecanemab-irmb)… EP News Bureau Jul 31, 2025 Data showed LEQEMBI slowed clinical decline by 1.75 points on CDR-SB at four years compared to the natural history of Alzheimer’s…
